Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
The short version
GTBL aims to grow its top line on a high-teen percentage basis over the next 3 to 5 years. FY26 revenue and profitability remained stable and in line with previous years, despite some production challenges. - GTBL was sold out in capacity, limiting growth; however, recent investments in fermentation and API facilities are expected to drive future growth. - Management aims for high-teen percentage growth annually over the next 3-5 years. - New acquisitions (MicroBiopharm and Sanofi brands) expected to add to revenues and earnings after integration and stabilization. - Synergies from acquisitions anticipated to start within the first year and contribute significantly. - EBITDA margins expected to be maintained close to current levels post-integration. - Focus on transforming GTBL into a fermentation-based CDMO with broader capabilities to capture higher-value opportunities. - Raising equity (~INR 1,000 crores) and debt (~INR 2,000 crores) planned to support growth.
From Gujarat Themis Biosyn Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- GTBL aims to grow its top line on a high-teen percentage basis over the next 3 to 5 years.
- With expanded capacity investments, the company expects increasing asset turns and quarter-on-quarter growth in revenues.
- The integration of recent acquisitions like MicroBiopharm and Sanofi’s portfolio is expected to add significant top-line and earnings growth.
- MicroBiopharm acquisition will enable GTBL to enter higher value fermentation-based CDMO space, expanding capabilities in immunosuppressants, oncology, peptides, plasmids, precision fermentation, enzyme engineering, and ADCs.
- Sanofi portfolio acquisition secures existing bread-and-butter APIs and opens up formulations, improving margin and revenue through better distribution and integration of API production.
2 more points from Gujarat Themis Biosyn Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gujarat Themis Biosyn Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Most of the capex is already completed by the company with only INR10-15 crores left for last mile completion in FY27, along with some maintenance capex totaling around INR20 crores for the year. (Page 11)
- Over the last 3 years, incremental investment of around INR370 crores in gross block, including new fermentation facility, API facility, new R&D infrastructure, and hybrid power project. (Page 12)
- Focus on expansion projects execution and integrating recent acquisitions to commercialize new capabilities, broaden product portfolio while maintaining strong financial performance. (Page 19)
- Additional fermentation capacity expansion (practically doubled capacity), fully operational by end of August 2026, enabling increase in API manufacturing capabilities. (Page 9)
2 more points from Gujarat Themis Biosyn Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gujarat Themis Biosyn Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There is no explicit mention of the current or expected order book or pending orders in the transcript.
- However, Sachin Patel mentioned consistently being sold out in terms of capacity over the past few years, implying strong demand.
- The company has seen robust increase in sales volumes and a healthy demand outlook for products as per Q1 FY27 performance.
- Integration of recent acquisitions like MicroBiopharm and Sanofi portfolio is expected to lead to new projects and add to revenues.
2 more points from Gujarat Themis Biosyn Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Gujarat Themis Biosyn Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹44 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gujarat Themis Biosyn Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline Ltd (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
Arthneeti Pro · Annual
Gujarat Themis Biosyn Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gujarat Themis Biosyn Ltd Q1 FY27 results?
GTBL aims to grow its top line on a high-teen percentage basis over the next 3 to 5 years. FY26 revenue and profitability remained stable and in line with previous years, despite some production challenges. - GTBL was sold out in capacity, limiting growth; however, recent investments in fermentation and API facilities are expected to drive future growth. - Management aims for high-teen percentage growth annually over the next 3-5 years. - New acquisitions (MicroBiopharm and Sanofi brands) expected to add to revenues and earnings after integration and stabilization. - Synergies from acquisitions anticipated to start within the first year and contribute significantly. - EBITDA margins expected to be maintained close to current levels post-integration. - Focus on transforming GTBL into a fermentation-based CDMO with broader capabilities to capture higher-value opportunities. - Raising equity (~INR 1,000 crores) and debt (~INR 2,000 crores) planned to support growth.
What is Gujarat Themis Biosyn Ltd share price analysis?
Gujarat Themis Biosyn Ltd currently shows a below-average growth signal. The stock trades at a P/E of 85.3 with a market cap of ₹4,154 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gujarat Themis Biosyn Ltd planning capital expenditure?
Most of the capex is already completed by the company with only INR10-15 crores left for last mile completion in FY27, along with some maintenance capex totaling around INR20 crores for the year.
Keep Gujarat Themis Biosyn Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.